The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive factors for pathologic complete response (pCR) to trastuzumab (T)-based neoadjuvant chemotherapy in HER2+ breast cancer (BC) women treated in the National Cancer Institute (NCI) of Mexico.
Erika Sifuentes
No relevant relationships to disclose
Yanin Chavarri Guerra
No relevant relationships to disclose
F. Berenice Baez-Revueltas
No relevant relationships to disclose
Enrique Soto-Perez-de-Celis
No relevant relationships to disclose
Fernando Lara-Medina
No relevant relationships to disclose
Santiago Ruano
No relevant relationships to disclose
Cynthia Mayte Villarreal-Garza
No relevant relationships to disclose